479 related articles for article (PubMed ID: 26408304)
21. The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet chemotherapy: a meta-analysis of prospective randomized trials.
Hasegawa Y; Ando M; Maemondo M; Yamamoto S; Isa S; Saka H; Kubo A; Kawaguchi T; Takada M; Rosell R; Kurata T; Ou SH
Oncologist; 2015 Mar; 20(3):307-15. PubMed ID: 25657199
[TBL] [Abstract][Full Text] [Related]
22. Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer.
Smith J
Clin Ther; 2005 Oct; 27(10):1513-34. PubMed ID: 16330289
[TBL] [Abstract][Full Text] [Related]
23. Current status of targeted therapy for anaplastic lymphoma kinase-rearranged non-small cell lung cancer.
Solomon B; Wilner KD; Shaw AT
Clin Pharmacol Ther; 2014 Jan; 95(1):15-23. PubMed ID: 24091716
[TBL] [Abstract][Full Text] [Related]
24. [Targeted therapies in non-small cell lung cancer in 2014].
Leduc C; Besse B
Rev Mal Respir; 2015 Feb; 32(2):182-92. PubMed ID: 25704901
[TBL] [Abstract][Full Text] [Related]
25. [Adjuvant chemotherapy for resectable non-small cell lung cancer (NSCLC)].
Nakajima E; Katou H
Kyobu Geka; 2008 Jan; 61(1):4-8. PubMed ID: 18186265
[TBL] [Abstract][Full Text] [Related]
26. Looking for a new panacea in ALK-rearranged NSCLC: may be Ceritinib?
Rolfo C; Passiglia F; Russo A; Pauwels P
Expert Opin Ther Targets; 2014 Sep; 18(9):983-5. PubMed ID: 24998601
[TBL] [Abstract][Full Text] [Related]
27. Choroidal metastasis response to crizotinib in a ROS1-rearranged NSCLC patient.
Lu S; Azada MC; Ou SH
Lung Cancer; 2015 Feb; 87(2):207-9. PubMed ID: 25558789
[TBL] [Abstract][Full Text] [Related]
28. Advances towards the design and development of personalized non-small-cell lung cancer drug therapy.
Vari S; Pilotto S; Maugeri-Saccà M; Ciuffreda L; Cesta Incani U; Falcone I; Del Curatolo A; Ceribelli A; Gelibter A; De Maria R; Tortora G; Cognetti F; Bria E; Milella M
Expert Opin Drug Discov; 2013 Nov; 8(11):1381-97. PubMed ID: 24088065
[TBL] [Abstract][Full Text] [Related]
29. Adjuvant treatment of non-small-cell lung cancer: how do we improve the cure rates further?
Wozniak AJ; Gadgeel SM
Oncology (Williston Park); 2007 Feb; 21(2):163-71; discussion 171, 174, 179-82. PubMed ID: 17396481
[TBL] [Abstract][Full Text] [Related]
30. Personalized medicine for non-small-cell lung cancer.
Mok TS; Zhou Q; Leung L; Loong HH
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1601-11. PubMed ID: 20942631
[TBL] [Abstract][Full Text] [Related]
31. Crizotinib in the treatment of non--small-cell lung cancer.
Rothschild SI; Gautschi O
Clin Lung Cancer; 2013 Sep; 14(5):473-80. PubMed ID: 23790969
[TBL] [Abstract][Full Text] [Related]
32. Moving towards molecular-guided treatments: erlotinib and clinical outcomes in non-small-cell lung cancer patients.
Santarpia M; De Pas TM; Altavilla G; Spaggiari L; Rosell R
Future Oncol; 2013 Mar; 9(3):327-45. PubMed ID: 23469969
[TBL] [Abstract][Full Text] [Related]
33. Molecular targeted therapy for early-stage non-small-cell lung cancer: will it increase the cure rate?
Martinez P; Martinez-Marti A; Navarro A; Cedrés S; Felip E
Lung Cancer; 2014 May; 84(2):97-100. PubMed ID: 24582269
[TBL] [Abstract][Full Text] [Related]
34. Adjuvant Chemotherapy for Early-Stage Non-small Cell Lung Cancer.
Visbal AL; Leighl NB; Feld R; Shepherd FA
Chest; 2005 Oct; 128(4):2933-43. PubMed ID: 16236970
[TBL] [Abstract][Full Text] [Related]
35. Neoadjuvant Oncogene-Targeted Therapy in Early Stage Non-Small-Cell Lung Cancer as a Strategy to Improve Clinical Outcome and Identify Early Mechanisms of Resistance.
McCoach CE; Bivona TG; Blakely CM; Doebele RC
Clin Lung Cancer; 2016 Sep; 17(5):466-469. PubMed ID: 27378174
[TBL] [Abstract][Full Text] [Related]
36. Early-stage non-small-cell lung cancer: current perspectives in combined-modality therapy.
Bunn PA
Clin Lung Cancer; 2004 Sep; 6(2):85-98. PubMed ID: 15476594
[TBL] [Abstract][Full Text] [Related]
37. National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network.
Abrams J; Conley B; Mooney M; Zwiebel J; Chen A; Welch JJ; Takebe N; Malik S; McShane L; Korn E; Williams M; Staudt L; Doroshow J
Am Soc Clin Oncol Educ Book; 2014; ():71-6. PubMed ID: 24857062
[TBL] [Abstract][Full Text] [Related]
38. Systemic and targeted therapies for early-stage lung cancer.
Byron E; Pinder-Schenck M
Cancer Control; 2014 Jan; 21(1):21-31. PubMed ID: 24357738
[TBL] [Abstract][Full Text] [Related]
39. [Combined Therapy with Targeted Drugs in Lung Cancer].
Yano S
Gan To Kagaku Ryoho; 2016 Apr; 43(4):413-8. PubMed ID: 27220787
[TBL] [Abstract][Full Text] [Related]
40. The role of anaplastic lymphoma kinase inhibitors in the treatment of advanced nonsmall cell lung cancer.
D'Arcangelo M; Wynes MW; Hirsch FR
Curr Opin Oncol; 2013 Mar; 25(2):121-9. PubMed ID: 23385859
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
